SpineEx, which is developing spinal implants to improve spinal fusion surgeries, withdrew its plans for an initial public offering on Friday. It originally filed in September 2018 with a proposed deal size of $17 million.
The company did not disclose a reason for the withdrawal. Since its initial filing, the company announced in a press release that it had received 510(k) clearance from the FDA for its Sagittae lateral lumbar interbody fusion (LLIF) device.
The pre-revenue company is based in Fremont, CA, and was founded in 2017. It had planned to list on the Nasdaq under the symbol SPIX. ThinkEquity was set to be the sole bookrunner on the deal.
